Ra Capital Management, L.P. - Jun 13, 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Purchase	$158K	+20K	+0.55%	$7.90	3.69M	Jun 13, 2022	See footnotes	F1, F4
transaction	ANTX	Common Stock	Purchase	$489K	+61.4K	+1.67%	$7.97	3.75M	Jun 14, 2022	See footnotes	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	These securities include 3,271,051 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund") and 415,612 shares held by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
F2	This transaction was executed in multiple trades at prices ranging from $7.725 to $8.00; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3	These securities include 3,332,475 shares held directly by the Fund and 415,612 shares held by Nexus Fund II.
F4	RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.